Informed Consent in Research

No. Trust in the researcher does not replace the subject's right to informed choice. Consent requires: (1) disclosure of material facts, (2) comprehension, and (3) voluntariness. Even if subject trusts you, you have an ethical and legal duty to disclose risks and allow time for understanding and decision. Do not accept blanket trust as waiver of informed consent. Encourage subject to ask questions, take time to think, and demonstrate understanding before enrollment. If subject remains unwilling to engage in consent discussion, that reluctance is a red flag: subject may not truly understand what they are agreeing to. Consider whether this subject is appropriate for enrollment until genuine informed consent can be obtained.

Therapeutic misconception is common even when research is explicitly non-therapeutic. Prevent it by: (1) Using separate language for research vs. therapeutic benefit: 'The goal of this study is to learn how the drug works in healthy people. This research may not benefit you personally, but findings will help future patients.' (2) Explicitly stating no expectation of clinical benefit: 'You should not enroll in this study expecting it to treat any condition or improve your health.' (3) Distinguishing study procedures from clinical care: 'These blood tests are research tests, not clinical tests. You will not receive results or diagnosis from these tests.' (4) Discussing what happens if harms occur: 'If you experience side effects, we will monitor and treat symptoms medically, but the goal of the study is research, not your treatment.' (5) Assessing understanding via teach-back: ask subject 'What do you expect to gain personally from this study?' If subject mentions health benefit, clarify that this is non-therapeutic research. Document this discussion in research records.

No single method is mandated universally; regulatory requirements vary. US Common Rule requires documentation that informed consent was obtained but does not specify comprehension assessment method. NIH recommends documenting comprehension, suggesting teach-back or quiz. Best practice combines methods: (1) Documented discussion: record that you discussed key elements (purpose, procedures, risks, benefits, alternatives, withdrawal) with subject and subject asked/answered questions. (2) Teach-back: ask subject to summarize in own words what research involves ('Tell me what you'll be doing if you enroll in this study'; 'What risks were we just talking about?'). (3) Comprehension assessment: for complex research or vulnerable populations, administer brief quiz (4-6 items covering key facts: research purpose, major procedures, major risks, voluntary participation, right to withdraw). Subjects scoring <80% should receive additional education and retest until adequate comprehension demonstrated. Document assessment results in records. Combination of methods is strongest evidence of informed consent.

Video can supplement but should not replace paper consent. Video consent is helpful for: (1) ensuring consistent delivery of information across multiple sites; (2) demonstrating that researcher presented material accurately; (3) confirming subject understood in real-time (video captures comprehension discussion). However, video alone has limitations: (1) subject cannot reference document later if questions arise; (2) video creates audit trail that may deter some participation; (3) technical issues (audio quality, video loss) may compromise record. Best practice: provide written consent form, use video as supplement to discussion (subject watches explanation of research, then discusses and signs form), and retain both video and written consent in records. Do not substitute video for written form without explicit regulatory approval from your IRB.

Payment to research subjects is permitted and common, but amount must be reasonable and not so large as to cloud subject's judgment (undue inducement). Guidelines vary: (1) Federal guidance (45 CFR 46.111): compensation must be 'reasonable' and 'not coercive.' No specific dollar limit; depends on participant burden and local economic context. (2) IRB practice: typical approach is to compensate proportional to time/burden (e.g., $15–30/hour for interview research, $50–200 per blood draw in clinical studies). (3) Test for undue inducement: would a reasonable person in participant's economic situation find incentive so large that they would overlook research risks or misrepresent eligibility? If yes, incentive is likely undue. Example: offering $5,000 to healthy volunteer for Phase 1 drug safety study in low-income community might be undue; same amount for 5-year follow-up cohort study involving minimal risk is reasonable. Disclose compensation amount in consent form; IRB will review adequacy. Do not offer 'bonus' payments for completing risky procedures, as this incentivizes risk-taking.

Voluntary consent is particularly difficult to obtain from vulnerable populations due to coercive environment or power imbalances. Protect by: (1) INDEPENDENT RECRUITER: use researcher not in direct authority over subject (not their physician, warden, employer). If independence impossible (e.g., hospitalized patient), implement other safeguards. (2) EXPLICIT NON-PENALTY: state clearly in consent 'Your choice whether to participate will not affect your [medical care / release date / job].' Do not assume subject believes this; explain and document. (3) ALLOWED TIME: give subject time to decide—do not rush consent in hospital, jail, or power-imbalanced settings. (4) INDEPENDENT ADVOCATE: for prisoners and some vulnerable populations, provide patient advocate or ombudsperson to review consent process and advocate for subject interests. (5) REDUCED RISK REQUIREMENT: consider limiting research to minimal-risk studies in vulnerable populations. (6) EXTRA PROTECTION FOR MINORS: dual consent (parent + child assent), independent review of consent process. Document all safeguards in IRB protocol and research records; IRB will verify that vulnerability protections are adequate.